WIC
ICPT

Woodmont Investment Counsel’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Woodmont Investment Counsel’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-55
Closed -$9K – 647
2016
Q3 		$9K Buy
+55
New +$8.67K ﹤0.01% 486
2016
Q2 		– Sell
-55
Closed -$7K – 474
2016
Q1 		$7K Hold
55
– – ﹤0.01% 442
2015
Q4 		$8K Buy
+55
New +$9.31K ﹤0.01% 446

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Woodmont Investment Counsel's ICPT Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2016, closing a stake of 55 shares — an estimated $9K sold.

Woodmont Investment Counsel first reported a position in ICPT in Q4 2015 and held it in 3 quarters. The position peaked at $9K in Q3 2016. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 55 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $9K.
  • Woodmont Investment Counsel first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2015 and held it in 3 quarters.
  • Woodmont Investment Counsel's Intercept Pharmaceuticals, Inc. position peaked at $9K in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.